Ying-En Lee1, Hong-Lin He2, Tzu-Ju Chen3, Sung-Wei Lee4, I-Wei Chang5, Chung-Hsi Hsing6, Chien-Feng Li7. 1. Department of Anesthesiology, Kaohsiung Chang Gung Memorial Hospital and Chang Gung University College of Medicine Kaohsiung, Taiwan. 2. Department of Pathology, E-DA Hospital, I-Shou University Kaohsiung, Taiwan ; Institute of Biomedical Science, National Sun Yat-Sen University Kaohsiung, Taiwan. 3. Department of Pathology, Chi-Mei Medical Center Tainan, Taiwan. 4. Department of Radiation Oncology, Chi-Mei Medical Center Liouying, Tainan, Taiwan. 5. Department of Pathology, E-DA Hospital, I-Shou University Kaohsiung, Taiwan. 6. Department of Anesthesiology, Chi-Mei Medical Center Tainan, Taiwan. 7. Department of Pathology, Chi-Mei Medical Center Tainan, Taiwan ; National Institute of Cancer Research, National Health Research Institutes Tainan, Taiwan ; Department of Biotechnology, Southern Taiwan University of Science and Technology Tainan, Taiwan ; Institute of Clinical Medicine, Kaohsiung Medical University Kaohsiung, Taiwan.
Abstract
BACKGROUND: By data mining from published transcriptomic databases, we identified RAP2A as a significantly upregulated gene in nasopharyngeal carcinoma (NPC) tissues. RAP2A, a member of the RAS oncogene family, is involved in the process of GTP binding and GTPase activity. The aim of this study was to evaluate the expression of RAP2A and its prognostic impact in patients with early and locoregionally advanced NPC. METHODS: RAP2A immunohistochemistry was performed for 124 NPC patients who were receiving standard treatment and had no initial distal metastasis. We also performed Western blotting to evaluate the endogenous protein expression of RAP2A in NPC cells and non-neoplastic mucosal cells. The result of RAP2A expression was further correlated with clinicopathological variables, disease-specific survival (DSS), distant metastasis-free survival (DMeFS), and local recurrence-free survival (LRFS). RESULTS: High expression of RAP2A was significantly associated with advanced primary tumor status (P = 0.024) and advanced TNM stage (P = 0.006). In univariate analysis, high expression of RAP2A served as a significant prognostic factor for inferior DSS (P < 0.0001), DMeFS (P < 0.0001), and LRFS (P < 0.0001). In multivariate analysis, RAP2A overexpression still independently predicted worse DSS (hazard ratio [HR] = 2.976, P < 0.001), DMeFS (HR = 4.233, P < 0.001), and LRFS (HR = 4.156, P < 0.001). Moreover, Both HONE1 and TW01 NPC cells, but not non-neoplastic DOK cells demonstrated significantly increased RAP2A expression. CONCLUSION: Overexpression of RAP2A is associated with advanced disease status and may therefore be an important prognosticator for poor outcomes in NPC, as well as a potential therapeutic target to aid in developing effective treatment modalities.
BACKGROUND: By data mining from published transcriptomic databases, we identified RAP2A as a significantly upregulated gene in nasopharyngeal carcinoma (NPC) tissues. RAP2A, a member of the RAS oncogene family, is involved in the process of GTP binding and GTPase activity. The aim of this study was to evaluate the expression of RAP2A and its prognostic impact in patients with early and locoregionally advanced NPC. METHODS:RAP2A immunohistochemistry was performed for 124 NPC patients who were receiving standard treatment and had no initial distal metastasis. We also performed Western blotting to evaluate the endogenous protein expression of RAP2A in NPC cells and non-neoplastic mucosal cells. The result of RAP2A expression was further correlated with clinicopathological variables, disease-specific survival (DSS), distant metastasis-free survival (DMeFS), and local recurrence-free survival (LRFS). RESULTS: High expression of RAP2A was significantly associated with advanced primary tumor status (P = 0.024) and advanced TNM stage (P = 0.006). In univariate analysis, high expression of RAP2A served as a significant prognostic factor for inferior DSS (P < 0.0001), DMeFS (P < 0.0001), and LRFS (P < 0.0001). In multivariate analysis, RAP2A overexpression still independently predicted worse DSS (hazard ratio [HR] = 2.976, P < 0.001), DMeFS (HR = 4.233, P < 0.001), and LRFS (HR = 4.156, P < 0.001). Moreover, Both HONE1 and TW01 NPC cells, but not non-neoplastic DOK cells demonstrated significantly increased RAP2A expression. CONCLUSION: Overexpression of RAP2A is associated with advanced disease status and may therefore be an important prognosticator for poor outcomes in NPC, as well as a potential therapeutic target to aid in developing effective treatment modalities.
Authors: Lizhi Zhang; Li Chenwei; Redah Mahmood; Kenneth van Golen; Joel Greenson; Gangyong Li; Nisha J D'Silva; Xiangquan Li; Charles F Burant; Craig D Logsdon; Diane M Simeone Journal: Cancer Res Date: 2006-01-15 Impact factor: 12.701
Authors: David S Liu; Sanne J M Hoefnagel; Oliver M Fisher; Kausilia K Krishnadath; Karen G Montgomery; Rita A Busuttil; Andrew J Colebatch; Matthew Read; Cuong P Duong; Wayne A Phillips; Nicholas J Clemons Journal: Oncotarget Date: 2016-12-13